Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry

Prior treatment

• History of fracture of the femoral neck prior to the diagnosis of hematologic malignancies
• Corticotherapy \> 3 months at a dose \> 7.5mg/day prior to the diagnosis of hematological disease

Other illness

• Hematologic malignancies other than AML
• Primary or secondary osteoporosis known to the diagnosis of hematologic malignancies

Lab values

• Pathologies influencing bone metabolism: known inflammatory rheumatism (rheumatoid arthritis, ...), primary hyperparathyroidism, chronic renal failure (GFR \< or = at 30ml / min / 1.73m2)

Age

• History of neoplasia with bone involvement (sarcoma, multiple myeloma, metastasis...) and/or any solid cancer less than 5 years old

Other

• Person under guardianship or curatorship, or unable to understand the purpose of the study.
• Known bone involvement related to AML at diagnosis
• Autograft or anterior allograft
• Pregnant or lactating woman

• Cytological diagnosis of acute myeloid leukemia (AML) with indication for a first-line allo-HSCTs transplant
• Patient affiliated to the social security system
• For women of childbearing age, use of reliable contraception throughout the study in accordance with the CPR of the drugs used.
• The patient must be able to comply with study visits and per protocol procedures
• Patient who has been informed of the study and has signed his informed consent